XSPRAY
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Xspray Pharma is a pharmaceutical company with several product candidates in clinical development that uses the patented HyNap technology to create improved versions of marketed protein kinase inhibitors. The drug candidate Dasynoc® is an amorphous form of dasatinib and is undergoing FDA review for market approval. Xspray Pharma's product portfolio also includes XS003-nilotinib, XS008-axitinib and XS025-cabozantinib.
Read moreEPS (adj.)
Dividend %
Interim report Q2'26
Interim report Q3'26
Annual report '26
Don't miss out - create an account and get all the possible benefits